A Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination With Trametinib in Anti-EGFR-Refractory Stage IV Colorectal Cancer Patients
Latest Information Update: 21 Jan 2025
At a glance
- Drugs Panitumumab (Primary) ; Trametinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
Most Recent Events
- 15 Jan 2025 Planned End Date changed from 31 Jan 2025 to 31 Jan 2026.
- 15 Jan 2025 Planned primary completion date changed from 31 Jan 2025 to 31 Jan 2026.
- 20 Dec 2023 Planned End Date changed from 31 Jan 2024 to 31 Jan 2025.